The global business climate is ever-evolving, and 2025 looks like it may be particularly challenging. Nowhere is that more evident than in the biopharma space, which is contending with multiple factors including a new administration in the US, new regulatory requirements in the EU, supply chain issues, and an uncertain economy. Despite these obstacles, however,…...